News|Articles|June 13, 2016

FDA Releases Guidance on Osteoporosis Treatment

The agency published guidance on the nonclinical evaluation of osteoporosis treatments.

On June 13, 2016, FDA released draft guidance on the nonclinical evaluation of treatments for osteoporosis. The guidance provides FDA’s recommendations for designing nonclinical studies of osteoporosis biopharmaceuticals.

According to FDA, long-term nonclinical bone quality studies should be conducted for osteoporosis treatments because of concerns about long-term adverse effects of these drugs on bone quality and “because there are no validated and reliable methods for the noninvasive assessment of bone quality in humans.” The guidance addresses toxicology, bone quality, and biopharmaceutical nonclinical studies. Regulatory aspects and anabolic agents are also discussed.

Source: FDA


Related to this article

Quality inspector walking through processing area with stainless tanks and tablet | Image Credit: ©Surachai -stock.adobe.com
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.